Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction
Objectives. A single-arm prospective study was conducted among Japanese patients with type 2 diabetes having preserved ejection fraction. The aim was to investigate (1) whether liraglutide therapy could improve B-type natriuretic peptide (BNP) levels and diastolic cardiac function assessed by the E-...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/8838026 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559806878056448 |
|---|---|
| author | Kunimasa Yagi Teruhiko Imamura Hayato Tada Daisuke Chujo Jianhui Liu Yuuki Shima Azusa Ohbatake Yukiko Miyamoto Satoko Okazaki Naoko Ito Kaoru Nakano Masataka Shikata Asako Enkaku Akiko Takikawa Hisae Honoki Shiho Fujisaka Hideki Origasa Kazuyuki Tobe |
| author_facet | Kunimasa Yagi Teruhiko Imamura Hayato Tada Daisuke Chujo Jianhui Liu Yuuki Shima Azusa Ohbatake Yukiko Miyamoto Satoko Okazaki Naoko Ito Kaoru Nakano Masataka Shikata Asako Enkaku Akiko Takikawa Hisae Honoki Shiho Fujisaka Hideki Origasa Kazuyuki Tobe |
| author_sort | Kunimasa Yagi |
| collection | DOAJ |
| description | Objectives. A single-arm prospective study was conducted among Japanese patients with type 2 diabetes having preserved ejection fraction. The aim was to investigate (1) whether liraglutide therapy could improve B-type natriuretic peptide (BNP) levels and diastolic cardiac function assessed by the E-wave to E′ ratio (E/E′) using transthoracic echocardiography (TTE), and (2) whether E/E′ contributed to BNP improvement independent of bodyweight reduction (UMIN000005565). Methods. Patients with type 2 diabetes and left ventricular ejection fraction LVEF≥40% without heart failure symptoms were enrolled, and daily injection with liraglutide (0.9 mg) was introduced. Cardiac functions were assessed by TTE before and after 26 weeks of liraglutide treatment. Diastolic cardiac function was defined as septal E/E′≥13.0. Results. Thirty-one patients were analyzed. BNP and E/E′ improved, with BNP levels declining from 36.8±30.5 pg/mL to 26.3±25.9 pg/mL (p=0.0014) and E/E′ dropping from 12.7±4.7 to 11.0±3.3 (p=0.0376). The LVEF showed no significant changes. E/E′ improved only in patients with E/E′≥13.0. Favorable changes in E/E′ were canceled when adjusted for body mass index (BMI). Multivariate linear regression analysis revealed that the left ventricular diastolic diameter and ∆E/E′/∆BMI contributed to ∆BNP/baseline BNP (p=0.0075, R2=0.49264). Conclusions. Liraglutide had favorable effects on BNP and E/E′ but not on LVEF. E/E′ improvement was only seen in patients with diastolic cardiac function. Body weight reduction affected the change of E/E′. The BMI-adjusted E/E′ significantly contributed to the relative change of BNP. GLP-1 analog treatment could be considered a therapeutic option against diabetic diastolic cardiac dysfunction regardless of body weight. This trial is registered with the University Hospital Medical Information Network in Japan, with clinical trial registration number: UMIN000005565. |
| format | Article |
| id | doaj-art-fe4cfe97412c473ea8a9ffe0f017a984 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-fe4cfe97412c473ea8a9ffe0f017a9842025-02-03T01:29:21ZengWileyJournal of Diabetes Research2314-67452314-67532021-01-01202110.1155/2021/88380268838026Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection FractionKunimasa Yagi0Teruhiko Imamura1Hayato Tada2Daisuke Chujo3Jianhui Liu4Yuuki Shima5Azusa Ohbatake6Yukiko Miyamoto7Satoko Okazaki8Naoko Ito9Kaoru Nakano10Masataka Shikata11Asako Enkaku12Akiko Takikawa13Hisae Honoki14Shiho Fujisaka15Hideki Origasa16Kazuyuki Tobe171st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan2nd Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan2nd Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-0934, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan2nd Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-0934, Japan2nd Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-0934, Japan2nd Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-0934, Japan2nd Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-0934, Japan2nd Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-0934, Japan2nd Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa 920-0934, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, JapanBiostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, 2630 Sugitani, Toyama 934-0194, Japan1st Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 934-0194, JapanObjectives. A single-arm prospective study was conducted among Japanese patients with type 2 diabetes having preserved ejection fraction. The aim was to investigate (1) whether liraglutide therapy could improve B-type natriuretic peptide (BNP) levels and diastolic cardiac function assessed by the E-wave to E′ ratio (E/E′) using transthoracic echocardiography (TTE), and (2) whether E/E′ contributed to BNP improvement independent of bodyweight reduction (UMIN000005565). Methods. Patients with type 2 diabetes and left ventricular ejection fraction LVEF≥40% without heart failure symptoms were enrolled, and daily injection with liraglutide (0.9 mg) was introduced. Cardiac functions were assessed by TTE before and after 26 weeks of liraglutide treatment. Diastolic cardiac function was defined as septal E/E′≥13.0. Results. Thirty-one patients were analyzed. BNP and E/E′ improved, with BNP levels declining from 36.8±30.5 pg/mL to 26.3±25.9 pg/mL (p=0.0014) and E/E′ dropping from 12.7±4.7 to 11.0±3.3 (p=0.0376). The LVEF showed no significant changes. E/E′ improved only in patients with E/E′≥13.0. Favorable changes in E/E′ were canceled when adjusted for body mass index (BMI). Multivariate linear regression analysis revealed that the left ventricular diastolic diameter and ∆E/E′/∆BMI contributed to ∆BNP/baseline BNP (p=0.0075, R2=0.49264). Conclusions. Liraglutide had favorable effects on BNP and E/E′ but not on LVEF. E/E′ improvement was only seen in patients with diastolic cardiac function. Body weight reduction affected the change of E/E′. The BMI-adjusted E/E′ significantly contributed to the relative change of BNP. GLP-1 analog treatment could be considered a therapeutic option against diabetic diastolic cardiac dysfunction regardless of body weight. This trial is registered with the University Hospital Medical Information Network in Japan, with clinical trial registration number: UMIN000005565.http://dx.doi.org/10.1155/2021/8838026 |
| spellingShingle | Kunimasa Yagi Teruhiko Imamura Hayato Tada Daisuke Chujo Jianhui Liu Yuuki Shima Azusa Ohbatake Yukiko Miyamoto Satoko Okazaki Naoko Ito Kaoru Nakano Masataka Shikata Asako Enkaku Akiko Takikawa Hisae Honoki Shiho Fujisaka Hideki Origasa Kazuyuki Tobe Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction Journal of Diabetes Research |
| title | Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction |
| title_full | Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction |
| title_fullStr | Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction |
| title_full_unstemmed | Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction |
| title_short | Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction |
| title_sort | diastolic cardiac function improvement by liraglutide is mainly body weight reduction dependent but independently contributes to b type natriuretic peptide reduction in patients with type 2 diabetes with preserved ejection fraction |
| url | http://dx.doi.org/10.1155/2021/8838026 |
| work_keys_str_mv | AT kunimasayagi diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT teruhikoimamura diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT hayatotada diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT daisukechujo diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT jianhuiliu diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT yuukishima diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT azusaohbatake diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT yukikomiyamoto diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT satokookazaki diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT naokoito diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT kaorunakano diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT masatakashikata diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT asakoenkaku diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT akikotakikawa diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT hisaehonoki diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT shihofujisaka diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT hidekiorigasa diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction AT kazuyukitobe diastoliccardiacfunctionimprovementbyliraglutideismainlybodyweightreductiondependentbutindependentlycontributestobtypenatriureticpeptidereductioninpatientswithtype2diabeteswithpreservedejectionfraction |